Critical Analysis: Chiasma (CHMA) & KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals (NASDAQ: KALV) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Earnings & Valuation
This table compares KalVista Pharmaceuticals and Chiasma’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$625,000.00||155.41||-$16.21 million||N/A||N/A|
KalVista Pharmaceuticals has higher revenue and earnings than Chiasma.
Risk & Volatility
KalVista Pharmaceuticals has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
This table compares KalVista Pharmaceuticals and Chiasma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for KalVista Pharmaceuticals and Chiasma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
KalVista Pharmaceuticals currently has a consensus target price of $18.00, indicating a potential upside of 80.00%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe KalVista Pharmaceuticals is more favorable than Chiasma.
Insider and Institutional Ownership
75.7% of KalVista Pharmaceuticals shares are held by institutional investors. Comparatively, 50.4% of Chiasma shares are held by institutional investors. 49.1% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Chiasma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
KalVista Pharmaceuticals beats Chiasma on 8 of the 11 factors compared between the two stocks.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.